MedTrace Logo

Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer

NCT00394147 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2022-08-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to look at how well the combination of two chemotherapy drugs, pemetrexed (Alimta) and gemcitabine (Gemzar) work to treat your cancer.

Conditions

Interventions

DRUG

pemetrexed

pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle

DRUG

gemcitabine

gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle

Sponsors & Collaborators

Principal Investigators

  • Ranee Mehra, MD · Fox Chase Cancer Center - Medical Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-08-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00394147 on ClinicalTrials.gov